Condition: Contraception · Sponsor: Mylan Pharmaceuticals Inc
A single-centre, open-label, randomised, phase II study on the maintenance of ovulation inhibition after intentional application errors during 84 days of treatment with MR 130A 01 contraceptive transdermal patch
This description comes directly from the study's public registry record.
Erin R Larnerd · 3045545844 · erin.larnerd@viatris.com
Laura F Zachwieja · 304-680-0256 · laura.zachwieja@viatris.com
Always discuss trial participation with your own doctor first.
| dinox GmbH | Berlin, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07365904